Table 3.

Prime editing enrichment strategies

Strategy	Cells	Target locus	Selection	Editing pre-enrichment	Editing post-enrichment	Fold increase	Ref.
PEAR	HEK293T	FANCF	FACS	N.A	76%	N.A	[183]
PEAR	K562	FANCF	FACS	N.A	62%	N.A	[183]
PEAR	U2OS	EMX1	FACS	~ 15%	~ 40%	2.67-fold	[183]
PEAR	HUES9	FANCF	FACS		28%	7.8-fold	[183]
PEAR	HEK293T	HEK3/RUNX1/HEXA/ EMX1/DNMT/FANCF/ HBB/PRNP	FACS	N.A	Up to 84%	2.1- to 4.6-fold	[183]
Marker-free co-selection	K562	RNF2/RUNX1/FANCF/ EMX1	Drug selection	N.A	83%	N.A	[184]
Marker-free co-selection	HeLa	RNF2/RUNX1/FANCF/ EMX1	Drug selection	< 1%	26–59%	> 26-fold	[184]
Marker-free co-selection	K562	RUNX1 and FANCF	Drug selection	N.A	81% (RUNX1) and 64% (FANCF)	N.A	[184]
Marker-free co-selection	K562	EMX1 and RUNX1	Drug selection	N.A	63% (EMX1) and 78% (RUNX1)	N.A	[184]
Marker-free co-selection	HeLa	MTOR	Drug selection	4–17%	30–78%	4- to 8-fold	[184]
Marker-free co-selection	U2OS	MTOR	Drug selection	N.A	74–89%	N.A	[184]

N.A. not available